Company intelligence / Profile preview
Genespire
Milan, Lombardy, Italygenespire.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
Genespire has developed a proprietary immune shielded lentiviral vector platform for off-the-shelf gene therapies. Its lead candidate, GENE202 for methylmalonic acidemia, will enter Phase I/II trials following a major Series B financing. No clinical results have been published yet; programs are preclinical or entering early clinical development.
- Therapeutic areas
- ImmunologyMetabolic Disorders
- Modalities
- Gene therapyLentiviral vector-based therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SR-Tiget research institute collaborationOspedale San RaffaeleFondazione TelethonSofinnova PartnersXGEN VentureCDP Venture CapitalIndaco SGR
Beyond the preview
Go deeper on Genespire.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genespire.